reports
Arvind Ltd: 1 director
A director at Arvind Ltd sold 163,800 shares at 100.760INR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
ARVIND sees an upgrade to Slightly Positive due to a better fundamenta...
The general evaluation of ARVIND (IN), a company active in the Clothing & Accessories industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 31, 2021, the closing price was...
- Ashiq Mubarack
- David Nierengarten
- Jeffrey La Rosa
- Kambiz Yazdi
- Laura Chico
- Liana Moussatos
- Matthew Barcus
- Robert Driscoll
- Shveta Dighe
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ABUS ARBUTUS BIOPHARMA CORP.
ARVIND ARVIND
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
BOLD AUDENTES THERAPEUTICS INC.
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
SRRA SIERRA ONCOLOGY
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ACER ACER THERAPEUTICS
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
DOVA DOVA PHARMACEUTICALS INC.
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ARAV ARAVIVE
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
ORTX REGULUS THERAPEUTICS
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
TPTX TCR2 THERAPEUTICS
KRTX TURNING POINT THERAPEUTICS
KARUNA THERAPEUTICS INC.
- Ashiq Mubarack
- David Nierengarten
- Jeffrey La Rosa
- Kambiz Yazdi
- Laura Chico
- Liana Moussatos
- Matthew Barcus
- Robert Driscoll
- Shveta Dighe
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ARVIND ARVIND
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
BOLD AUDENTES THERAPEUTICS INC.
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
SRRA SIERRA ONCOLOGY
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ACER ACER THERAPEUTICS
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
DOVA DOVA PHARMACEUTICALS INC.
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARAV ARAVIVE
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
ORTX REGULUS THERAPEUTICS
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
TPTX TCR2 THERAPEUTICS
KRTX TURNING POINT THERAPEUTICS
KARUNA THERAPEUTICS INC.
- Wedbush Research
ACN ACCENTURE PLC CLASS A
XNCR XENCOR INC.
W9N WNS (HOLDINGS) LIMITED SPONSORED ADR
WITN WIPRO LTD
EG1 VIRTUSA CORPORATION
TSLA TESLA INC
TSCO TRACTOR SUPPLY COMPANY
STML STEMLINE THERAPEUTICS INC
NVCR NOVOCURE LTD.
MGNX MACROGENICS INC.
LEN LENNAR CORPORATION CLASS A
KURA KURA ONCOLOGY INC.
KBH KB HOME
35G GENPACT LIMITED
FPRX FIVE PRIME THERAPEUTICS INC.
EXLS EXLSERVICE HOLDINGS INC.
EPZM EPIZYME INC.
EPAM EPAM SYSTEMS INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BBY BEST BUY CO. INC.
ACOR ACORDA THERAPEUTICS INC.
ARVIND ARVIND
ALPN ALPINE SELECT AG
GLOB GLOBANT SA
VFC V.F. CORPORATION
MRUS MERUS B V
GTHX G1 THERAPEUTICS
AMZN AMAZON.COM INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARAV ARAVIVE
STRO SUTRO BIOPHARMA
HARP HARPOON THERAPEUTICS
TCRR TCR2 THERAPEUTICS
TPTX TURNING POINT THERAPEUTICS
CHWY CHEWY INC. CLASS A
- Ashiq Mubarack
- David Nierengarten
- Jeffrey La Rosa
- Matthew Barcus
- Robert Driscoll
STML STEMLINE THERAPEUTICS INC
NVCR NOVOCURE LTD.
MGNX MACROGENICS INC.
KURA KURA ONCOLOGY INC.
FPRX FIVE PRIME THERAPEUTICS INC.
EPZM EPIZYME INC.
BPMC BLUEPRINT MEDICINES CORP.
ARVIND ARVIND
ALPN ALPINE SELECT AG
MRUS MERUS B V
GTHX G1 THERAPEUTICS
RCUS ARCUS BIOSCIENCES
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARAV ARAVIVE
STRO SUTRO BIOPHARMA
HARP HARPOON THERAPEUTICS
TCRR TCR2 THERAPEUTICS
TPTX TURNING POINT THERAPEUTICS
- Wedbush Research
KMX CARMAX INC.
GPN GLOBAL PAYMENTS INC.
VRNS VARONIS SYSTEMS INC.
V VISA INC. CLASS A
SQ SQUARE INC. CLASS A
PYPL PAYPAL HOLDINGS INC
PRGS PROGRESS SOFTWARE CORPORATION
GPC GENUINE PARTS COMPANY
GOOGL ALPHABET INC. CLASS A
FISV FISERV INC.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
AZO AUTOZONE INC.
AAP ADVANCE AUTO PARTS INC.
ARVIND ARVIND
ADS ALLIANCE DATA SYSTEMS CORPORATION
GTHX G1 THERAPEUTICS
ORLY O'REILLY AUTOMOTIVE
AMZN AMAZON.COM INC.
HOG HARLEY-DAVIDSON INC.
NKE NIKE INC. CLASS B
MSFT MICROSOFT CORPORATION
HARP HARPOON THERAPEUTICS
- Ashiq Mubarack
- Robert Driscoll
MOSL: ANNUAL REPORT THREADBARE (ART) | ARVIND FY18-Rising capital inte...
ANNUAL REPORT THREADBARE (ART) | ARVIND FY18: Rising capital intensity dents return ratios Arvind Limited’s (ARVND) FY18 annual report indicated a weak operating performance with EBITDA remaining muted at INR9.6b (FY17: INR9.4b) and margin declining by 124bp to 9%, primarily on account of declining margins in the textiles business (13% v/s 16% in FY17) and rising revenue share of lower margin branded apparels business (36% v/s 32% in FY17). Increasing capex over the years has led to rising ...
MOSL: ARVIND (Neutral)-Weak consumer demand impacts growth-NCLT approv...
Arvind: Weak consumer demand impacts growth; NCLT approves demerger (ARVND IN, Mkt Cap USD1.2b, CMP INR346, TP INR397, 15% Upside, Neutral) Revenue up 12% YoY, EBITDA margin expands 100bp YoY: Revenue increased 12% YoY to INR30.5b (our estimate: INR29.5b) in 2QFY19. Branded Apparels business grew by 9% YoY to INR12.3b (unadjusted: +13% YoY to INR11.6b; stated higher due to Ind-AS adjustment) and Textiles business by 6% YoY to INR14.9b. EBITDA rose 27% YoY to INR2.8b (our estimate: INR2.6b...
MOSL: ARVIND (Neutral)-Beat on all fronts-On track with margin expansi...
Arvind: Beat on all fronts; On track with margin expansion in Brands & Retail (ARVND IN, Mkt Cap USD1.6b, CMP INR420, TP INR454, 8% Upside, Neutral) Revenue, EBIDTA, PAT exceed estimate: Revenue increased 10% YoY to INR28.6b (est. of INR26b) in 1QFY19, led by Brands & Retail business (up 14% YoY to INR10.1b; INR890m unadjusted – stated higher due to Ind-AS adjustment + one-time impact from agreement changes). Textiles business too grew by 2% YoY to INR15.6b. EBITDA grew 18% YoY to INR2.5b...
MOSL: ARVIND (Neutral) - Beat on all fronts - Brands to drive margin e...
ARVIND: Beat on all fronts; Brands to drive margin expansion (ARVND IN, Mkt Cap USD1.7b, CMP INR438, TP INR460, 5% Upside, Neutral) Revenue, EBIDTA and PAT exceed estimate: Revenue rose 21.3% YoY to INR29.9b (est. of INR28.2b) in 4QFY18. Brands & Retail business grew by 28% YoY to INR10.7b, while Textiles business grew by 9% YoY to INR16b. EBITDA rose 26.4% YoY to INR2.9b (est. of INR2.4b), driven by increased profitability in Brands. EBITDA margin expanded 40bp YoY to 9.8% (est. of 8.8%)...
MOSL: ARVIND (Neutral)-Brands business pull up overall growth
Arvind: Brands business pull up overall growth (ARVND IN, Mkt Cap USD1.7b, CMP INR412, TP INR402, 2% Downside, Neutral) Revenue, EBITDA in-line; PAT above estimates: Arvind’s (ARVND) revenue grew 15.9% YoY to INR27.05b (est. of INR26.7b) in 3QFY18. Brands & Retail business grew by 23.6% YoY to INR9.6b, while Textiles business grew by 9.4% YoY to INR15.3b. EBITDA rose 5% YoY to INR2,484m (est. of INR2,515m), driven by increased profitability in Brands. However, Textiles continued to face pres...
MOSL: ARVIND (Neutral)-Demerger of brands and retail business to creat...
​Arvind: Demerger of brands and retail business to create long-term(ARVNDIN, Mkt Cap USD1.8b, CMP INR414, TP INR425, 3% Upside, Neutral)GST transition, coupled with high cotton prices, impacts margins: ARVIND’s revenue grew 12% YoY to INR26.3b (est. of INR26.1b) in 2QFY18. Brands and Retail grew 34% YoY to INR10.3b, while Textiles grew 1% YoY to INR14.4b. EBITDA declined 9% YoY to INR2,123m (est. of INR2,506m), with the margin contracting 190bp to 8.1% (est. of 9.6%) on account of higher raw...
MOSL: ARVIND (Neutral)-Pressure on Textiles-Brand & Retail to drive gr...
​ARVIND: Pressure on Textiles; Brand & Retail to drive growth(ARVND IN, Mkt Cap USD1.5b, CMP INR365, TP INR375, 10% Upside, Neutral)Branded Apparels segment drives growth: ARVND’s revenue grew 17.6% YoY to INR24.7b (est. of INR23b) in 1QFY18, led by growth of 39.6% YoY in Branded Apparels. EBITDA stood at INR2,070m (est. of INR2,212m) v/s INR2,445m in 1QFY17. EBITDA margin contracted 320bp YoY to 8.4% (est. of 9.6%) on account of higher raw material costs (+290bp YoY). Adj. PAT declined to I...
MOSL: ARVIND (Neutral)-GST to have a transitional impact-Continued pre...
​arvind: GST to have a transitional impact; Continued pressure on margins(ARVND IN, Mkt Cap USD1.5b, CMP INR367, TP INR362, 1% Downside, Neutral)Brands & Retail: Higher tax under GST to drive price hikesPrice hikes on the cards: Arvind’s (ARVND) Brand & Retail segment currently attracts a tax rate of ~11% (5.5% VAT, 3.5% service tax, ~2% excise) of transaction value (company billing and not MRP), which will be increased to 12% under GST for all apparels with transaction value greater than IN...
MOSL: ARVIND (Downgrading to Neutral)-Raw material and currency headwi...
​Arvind: Raw material and currency headwinds ahead; downgrading to Neutral(ARVND IN, Mkt Cap USD1.6b, CMP INR408, TP INR382, 6% Downside, Downgrade to Neutral)In-line revenue; EBITDA and PAT below estimates: Arvind's (ARVND) revenue grew 10.4% YoY to INR24.6b (est. of INR24.9b), led by strong growth in Brands & Retail (B&R) to INR8.3b (+22% YoY, driven by LTL growth of 5.4% in Power brands and 30.2% in Unlimited) and in Textiles to INR14.6b (+8% YoY). EBITDA declined to INR2.3b (est. of INR3b)...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.